PE20221256A1 - Anticuerpos dirigidos a flt3 y uso de los mismos - Google Patents
Anticuerpos dirigidos a flt3 y uso de los mismosInfo
- Publication number
- PE20221256A1 PE20221256A1 PE2022000635A PE2022000635A PE20221256A1 PE 20221256 A1 PE20221256 A1 PE 20221256A1 PE 2022000635 A PE2022000635 A PE 2022000635A PE 2022000635 A PE2022000635 A PE 2022000635A PE 20221256 A1 PE20221256 A1 PE 20221256A1
- Authority
- PE
- Peru
- Prior art keywords
- flt3
- variable domain
- chain variable
- complementarity determining
- determining region
- Prior art date
Links
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 title abstract 4
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 title 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 abstract 7
- 101710151245 Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 abstract 3
- 239000000427 antigen Substances 0.000 abstract 3
- 102000036639 antigens Human genes 0.000 abstract 3
- 108091007433 antigens Proteins 0.000 abstract 3
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 abstract 2
- 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 abstract 2
- 150000001413 amino acids Chemical class 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 229940126530 T cell activator Drugs 0.000 abstract 1
- 239000000611 antibody drug conjugate Substances 0.000 abstract 1
- 229940049595 antibody-drug conjugate Drugs 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 239000013604 expression vector Substances 0.000 abstract 1
- 229940127130 immunocytokine Drugs 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente invencion se refiere a proteinas con dominios variables de cadena pesada y cadena ligera de anticuerpos que pueden emparejarse para formar un sitio de union a antigeno dirigido a la tirosina quinasa 3 relacionada con Fms (FLT3) en una celula. Especificamente, se refiere a sitios de union al antigeno que se unen a FLT3, que comprenden: a) un dominio variable de cadena pesada (VH) que comprende la region determinante de complementariedad 1 (CDR1), la region determinante de complementariedad 2 (CDR2) y la region determinante de complementariedad 3 (CDR3) que comprenden las secuencias de aminoacidos SEQ ID NO: 11, 4 y 55, respectivamente, entre otros; y b) un dominio variable de cadena ligera (VL) que comprende la CDR1, CDR2 y CDR3 que comprenden las secuencias de aminoacidos SEQ ID NO: 6, 7 y 8, respectivamente, entre otros. Adicionalmente, el sitio de union al antigeno comprende un VH y un VL de SEQ ID NO: 53 y 42, respectivamente. Tambien se refiere a un conjugado anticuerpo-farmaco, una inmunocitocina, un activador de celulas T biespecifico, un receptor de antigenos quimericos (CAR), un acido nucleico aislado, un vector de expresion y una composicion farmaceutica. Dichas proteinas son utiles en el tratamiento del cancer.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962915120P | 2019-10-15 | 2019-10-15 | |
| PCT/US2020/055480 WO2021076554A1 (en) | 2019-10-15 | 2020-10-14 | Antibodies targeting flt3 and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20221256A1 true PE20221256A1 (es) | 2022-08-16 |
Family
ID=75538063
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2022000635A PE20221256A1 (es) | 2019-10-15 | 2020-10-14 | Anticuerpos dirigidos a flt3 y uso de los mismos |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20240228628A9 (es) |
| EP (1) | EP4045537A4 (es) |
| JP (1) | JP2022551757A (es) |
| KR (1) | KR20220082882A (es) |
| CN (1) | CN115348972A (es) |
| AR (1) | AR120222A1 (es) |
| AU (1) | AU2020366000A1 (es) |
| BR (1) | BR112022006817A2 (es) |
| CA (1) | CA3153801A1 (es) |
| CL (1) | CL2022000927A1 (es) |
| CO (1) | CO2022004743A2 (es) |
| IL (1) | IL292259A (es) |
| MX (1) | MX2022004291A (es) |
| PE (1) | PE20221256A1 (es) |
| TW (1) | TWI867066B (es) |
| WO (1) | WO2021076554A1 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202007482WA (en) | 2018-02-08 | 2020-09-29 | Dragonfly Therapeutics Inc | Antibody variable domains targeting the nkg2d receptor |
| CA3090236A1 (en) | 2018-02-08 | 2019-08-15 | Dragonfly Therapeutics, Inc. | Combination therapy of cancer involving multi-specific binding proteins that activate natural killer cells |
| MX2021001527A (es) | 2018-08-08 | 2021-06-15 | Dragonfly Therapeutics Inc | Proteínas de unión a nkg2d, cd16 y a un antígeno asociado a tumor. |
| MA53293A (fr) | 2018-08-08 | 2021-11-17 | Dragonfly Therapeutics Inc | Protéines de liaison multi-spécifiques se liant à bcma, nkg2d et cd16, et méthodes d'utilisation |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| WO2022173949A1 (en) * | 2021-02-10 | 2022-08-18 | WUGEN, Inc. | Polypeptides and their use in treatment of disease |
| WO2022187539A1 (en) | 2021-03-03 | 2022-09-09 | Dragonfly Therapeutics, Inc. | Methods of treating cancer using multi-specific binding proteins that bind nkg2d, cd16 and a tumor-associated antigen |
| US12162940B2 (en) | 2021-05-05 | 2024-12-10 | Immatics Biotechnologies Gmbh | BMA031 antigen binding polypeptides |
| EP4388008A1 (en) * | 2021-08-16 | 2024-06-26 | Hemogenyx Pharmaceuticals Llc | Anti-flt3 antibodies, cars, car t cells and methods of use |
| US20250049939A1 (en) * | 2021-12-10 | 2025-02-13 | Tubulis Gmbh | Novel flt3 antibodies and antibody-drug-conjugates based thereon, therapeutic methods and uses thereof in combination with tyrosine kinase inhibitors |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR071891A1 (es) * | 2008-05-30 | 2010-07-21 | Imclone Llc | Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano) |
| NL2014108B1 (en) * | 2015-01-09 | 2016-09-30 | Aduro Biotech Holdings Europe B V | Altered april binding antibodies. |
| US9974865B2 (en) * | 2015-03-09 | 2018-05-22 | Agensys, Inc. | Antibody drug conjugates (ADC) that bind to FLT3 proteins |
| JP2018523471A (ja) * | 2015-07-16 | 2018-08-23 | セレラント セラピューティクス インコーポレイテッド | システイン置換免疫グロブリン |
| MY201327A (en) * | 2017-06-02 | 2024-02-16 | Pfizer | Chimeric antigen receptors targeting flt3 |
| EP3630841A1 (en) * | 2017-06-02 | 2020-04-08 | Pfizer Inc. | Antibodies specific for flt3 and their uses |
| WO2019023097A1 (en) * | 2017-07-26 | 2019-01-31 | Smet Pharmaceutical Inc | ASYMMETRIC BISPECIFIC ANTIBODIES AND THEIR USE |
| AU2019207895A1 (en) * | 2018-01-12 | 2020-06-18 | Amgen Inc. | Anti-PD-1 antibodies and methods of treatment |
-
2020
- 2020-10-14 BR BR112022006817A patent/BR112022006817A2/pt not_active Application Discontinuation
- 2020-10-14 JP JP2022522653A patent/JP2022551757A/ja active Pending
- 2020-10-14 AR ARP200102839A patent/AR120222A1/es unknown
- 2020-10-14 CN CN202080072320.1A patent/CN115348972A/zh active Pending
- 2020-10-14 KR KR1020227016159A patent/KR20220082882A/ko active Pending
- 2020-10-14 US US17/769,257 patent/US20240228628A9/en active Pending
- 2020-10-14 EP EP20876423.3A patent/EP4045537A4/en active Pending
- 2020-10-14 TW TW109135527A patent/TWI867066B/zh active
- 2020-10-14 WO PCT/US2020/055480 patent/WO2021076554A1/en not_active Ceased
- 2020-10-14 CA CA3153801A patent/CA3153801A1/en active Pending
- 2020-10-14 MX MX2022004291A patent/MX2022004291A/es unknown
- 2020-10-14 AU AU2020366000A patent/AU2020366000A1/en active Pending
- 2020-10-14 PE PE2022000635A patent/PE20221256A1/es unknown
-
2022
- 2022-04-12 CL CL2022000927A patent/CL2022000927A1/es unknown
- 2022-04-13 CO CONC2022/0004743A patent/CO2022004743A2/es unknown
- 2022-04-13 IL IL292259A patent/IL292259A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL292259A (en) | 2022-06-01 |
| CL2022000927A1 (es) | 2022-10-28 |
| US20240228628A9 (en) | 2024-07-11 |
| WO2021076554A1 (en) | 2021-04-22 |
| MX2022004291A (es) | 2022-05-10 |
| CN115348972A (zh) | 2022-11-15 |
| WO2021076554A8 (en) | 2022-04-21 |
| EP4045537A4 (en) | 2024-07-17 |
| JP2022551757A (ja) | 2022-12-13 |
| TW202124449A (zh) | 2021-07-01 |
| CA3153801A1 (en) | 2021-04-22 |
| EP4045537A1 (en) | 2022-08-24 |
| AU2020366000A1 (en) | 2022-05-12 |
| CO2022004743A2 (es) | 2022-07-08 |
| AR120222A1 (es) | 2022-02-02 |
| KR20220082882A (ko) | 2022-06-17 |
| TWI867066B (zh) | 2024-12-21 |
| US20240132598A1 (en) | 2024-04-25 |
| BR112022006817A2 (pt) | 2022-07-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20221256A1 (es) | Anticuerpos dirigidos a flt3 y uso de los mismos | |
| PE20231851A1 (es) | Proteinas que se unen a nkg2d, cd16 y clec12a | |
| PE20220495A1 (es) | Receptores antigenicos quimericos y agentes de union dirigidos a dll3 | |
| PE20190120A1 (es) | Moleculas de union a bcma y metodos de uso de las mismas | |
| PE20211767A1 (es) | Anticuerpos anti-hla-g, composiciones que comprenden anticuerpos anti-hla-g y metodos de uso de anticuerpos anti-hla-g | |
| PE20170912A1 (es) | Conjugados de anticuerpo-farmaco | |
| PE20201255A1 (es) | Anticuerpos y conjugados de anticuerpo-farmaco especificos para cd123 y usos de los mismos | |
| PE20221580A1 (es) | Anticuerpos terapeuticos y sus usos | |
| ES3015105T3 (en) | Anti-cd3 epsilon antibodies | |
| PE20191546A1 (es) | Moleculas de union antigeno biespecificas que comprenden el clon 20h4.9 anti-41bb | |
| AR102732A1 (es) | Moléculas de unión a antígeno biespecíficas activadoras de células t | |
| PE20220142A1 (es) | Anticuerpos de cadena pesada que se unen al psma | |
| JP7579990B2 (ja) | 抗ネクチン－４抗体およびその使用 | |
| PE20241623A1 (es) | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y usos de los mismos | |
| AR065506A1 (es) | Anticuerpos antagonistas ox40 y su uso en el tratamiento de enfermedades | |
| HRP20200390T1 (hr) | Monoklonska antitijela protiv humanog antigena starenja b stanica (bcma) | |
| MX2018012433A (es) | Moleculas de union b7-h3 novedosas, conjugados anticuerpo-farmaco de los mismos y metodos de uso de los mismos. | |
| PE20191031A1 (es) | ANTICUERPOS ANTI-C1s Y METODOS DE USO DE LOS MISMOS | |
| PE20091269A1 (es) | Moleculas de union al receptor ox40 humano | |
| AR077088A1 (es) | Proteinas biespecificas de union a antigeno | |
| PE20120475A1 (es) | Anticuerpos especificos para dkk-1 | |
| ES3015094T3 (en) | Anti-hsa antibodies | |
| PE20230408A1 (es) | Anticuerpo anti-lilrb1 y usos del mismo | |
| PE20231187A1 (es) | Anticuerpos anti-par-2 y metodos de uso de los mismos | |
| PE20220763A1 (es) | Materiales y metodos para modular la inmunidad mediada por celulas t |